Danske Bank A S Purchases New Holdings in DexCom, Inc. $DXCM

Danske Bank A S acquired a new position in DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 195,049 shares of the medical device company’s stock, valued at approximately $13,137,000. Danske Bank A S owned about 0.05% of DexCom at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Norges Bank purchased a new position in shares of DexCom in the fourth quarter valued at approximately $483,356,000. AQR Capital Management LLC increased its position in shares of DexCom by 597.8% during the fourth quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock worth $205,932,000 after purchasing an additional 2,658,158 shares in the last quarter. Deutsche Bank AG purchased a new stake in shares of DexCom during the second quarter worth approximately $164,035,000. Employees Provident Fund Board acquired a new position in DexCom in the 4th quarter valued at $145,352,000. Finally, J. Stern & Co. LLP raised its stake in DexCom by 2,114.8% in the 4th quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company’s stock valued at $106,323,000 after purchasing an additional 1,529,641 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Price Performance

Shares of DXCM stock opened at $90.22 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The company has a market capitalization of $34.05 billion, a PE ratio of 35.66, a price-to-earnings-growth ratio of 1.52 and a beta of 1.41. The firm’s 50-day moving average is $77.15 and its two-hundred day moving average is $70.79. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $91.96.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.48 EPS. Analysts predict that DexCom, Inc. will post 2.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. UBS Group set a $96.00 target price on shares of DexCom and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a research note on Friday, May 1st. Deutsche Bank Aktiengesellschaft began coverage on shares of DexCom in a research report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price target on the stock. Piper Sandler reiterated an “overweight” rating and issued a $95.00 price objective (up from $88.00) on shares of DexCom in a report on Friday, July 31st. Finally, Truist Financial set a $93.00 target price on shares of DexCom and gave the stock a “buy” rating in a research note on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.71.

Insiders Place Their Bets

In other news, EVP Jon Coleman sold 4,912 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total value of $358,576.00. Following the transaction, the executive vice president owned 100,361 shares of the company’s stock, valued at $7,326,353. This represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the stock in a transaction on Monday, July 20th. The stock was sold at an average price of $76.32, for a total value of $2,042,017.92. Following the transaction, the insider owned 328,970 shares of the company’s stock, valued at approximately $25,106,990.40. This represents a 7.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 73,035 shares of company stock valued at $5,446,673. 0.28% of the stock is currently owned by insiders.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.